Unexpected complexity in the molecular diagnosis of spastic paraplegia 11.


Journal

Molecular genetics & genomic medicine
ISSN: 2324-9269
Titre abrégé: Mol Genet Genomic Med
Pays: United States
ID NLM: 101603758

Informations de publication

Date de publication:
Jun 2024
Historique:
revised: 04 04 2024
received: 29 01 2024
accepted: 21 05 2024
medline: 28 6 2024
pubmed: 28 6 2024
entrez: 28 6 2024
Statut: ppublish

Résumé

Spastic paraplegia 11 (SPG11) is the most prevalent form of autosomal recessive hereditary spastic paraplegia, resulting from biallelic pathogenic variants in the SPG11 gene (MIM *610844). The proband is a 36-year-old female referred for genetic evaluation due to cognitive dysfunction, gait impairment, and corpus callosum atrophy (brain MRI was normal at 25-years-old). Diagnostic approaches included CGH array, next-generation sequencing, and whole transcriptome sequencing. CGH array revealed a 180 kb deletion located upstream of SPG11. Sequencing of SPG11 uncovered two rare single nucleotide variants: the novel variant c.3143C>T in exon 17 (in cis with the deletion), and the previously reported pathogenic variant c.6409C>T in exon 34 (in trans). Whole transcriptome sequencing revealed that the variant c.3143C>T caused exon 17 skipping. We report a novel sequence variant in the SPG11 gene resulting in exon 17 skipping, which, along with a nonsense variant, causes Spastic Paraplegia 11 in our proband. In addition, a deletion upstream of SPG11 was identified in the patient, whose implication in the phenotype remains uncertain. Nonetheless, the deletion apparently affects cis-regulatory elements of the gene, suggesting a potential new pathogenic mechanism underlying the disease in a subset of undiagnosed patients. Our findings further support the hypothesis that the origin of thin corpus callosum in patients with SPG11 is of progressive nature.

Sections du résumé

BACKGROUND BACKGROUND
Spastic paraplegia 11 (SPG11) is the most prevalent form of autosomal recessive hereditary spastic paraplegia, resulting from biallelic pathogenic variants in the SPG11 gene (MIM *610844).
METHODS METHODS
The proband is a 36-year-old female referred for genetic evaluation due to cognitive dysfunction, gait impairment, and corpus callosum atrophy (brain MRI was normal at 25-years-old). Diagnostic approaches included CGH array, next-generation sequencing, and whole transcriptome sequencing.
RESULTS RESULTS
CGH array revealed a 180 kb deletion located upstream of SPG11. Sequencing of SPG11 uncovered two rare single nucleotide variants: the novel variant c.3143C>T in exon 17 (in cis with the deletion), and the previously reported pathogenic variant c.6409C>T in exon 34 (in trans). Whole transcriptome sequencing revealed that the variant c.3143C>T caused exon 17 skipping.
CONCLUSION CONCLUSIONS
We report a novel sequence variant in the SPG11 gene resulting in exon 17 skipping, which, along with a nonsense variant, causes Spastic Paraplegia 11 in our proband. In addition, a deletion upstream of SPG11 was identified in the patient, whose implication in the phenotype remains uncertain. Nonetheless, the deletion apparently affects cis-regulatory elements of the gene, suggesting a potential new pathogenic mechanism underlying the disease in a subset of undiagnosed patients. Our findings further support the hypothesis that the origin of thin corpus callosum in patients with SPG11 is of progressive nature.

Identifiants

pubmed: 38938072
doi: 10.1002/mgg3.2475
doi:

Substances chimiques

SPG11 protein, human 0
Proteins 0
Codon, Nonsense 0

Types de publication

Journal Article Case Reports

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2475

Informations de copyright

© 2024 The Author(s). Molecular Genetics & Genomic Medicine published by Wiley Periodicals LLC.

Références

Bauer, P., Winner, B., Schüle, R., Bauer, C., Häfele, V., Hehr, U., Bonin, M., Walter, M., Karle, K., Ringer, T. M., Rieß, O., Winkler, J., & Schöls, L. (2009). Identification of a heterozygous genomic deletion in the spatacsin gene in SPG11 patients using high‐resolution comparative genomic hybridization. Neurogenetics, 10(1), 43–48.
Benito‐Sanz, S., Aza‐Carmona, M., Rodríguez‐Estevez, A., Rica‐Etxebarria, I., Gracia, R., Campos‐Barros, Á., & Heath, K. E. (2012). Identification of the first PAR1 deletion encompassing upstream SHOX enhancers in a family with idiopathic short stature. European Journal of Human Genetics, 20(1), 125–127.
Boutry, M., Branchu, J., Lustremant, C., Pujol, C., Pernelle, J., Matusiak, R., Seyer, A., Poirel, M., Chu‐van, E., Pierga, A., Dobrenis, K., Puech, J. P., Caillaud, C., Durr, A., Brice, A., Colsch, B., Mochel, F., el Hachimi, K. H., Stevanin, G., & Darios, F. (2018). Inhibition of lysosome membrane recycling causes accumulation of gangliosides that contribute to neurodegeneration. Cell Reports, 23(13), 3813–3826.
Branchu, J., Boutry, M., Sourd, L., Depp, M., Leone, C., Corriger, A., Vallucci, M., Esteves, T., Matusiak, R., Dumont, M., Muriel, M. P., Santorelli, F. M., Brice, A., el Hachimi, K. H., Stevanin, G., & Darios, F. (2017). Loss of spatacsin function alters lysosomal lipid clearance leading to upper and lower motor neuron degeneration. Neurobiology of Disease, 102, 21–37.
Casali, C., Valente, E. M., Bertini, E., Montagna, G., Criscuolo, C., De Michele, G., Villanova, M., Damiano, M., Pierallini, A., Brancati, F., & Scarano, V. (2004). Clinical and genetic studies in hereditary spastic paraplegia with thin corpus callosum. Neurology, 62(2), 262–268.
Denora, P. S., Schlesinger, D., Casali, C., Kok, F., Tessa, A., Boukhris, A., Azzedine, H., Dotti, M. T., Bruno, C., Truchetto, J., Biancheri, R., Fedirko, E., di Rocco, M., Bueno, C., Malandrini, A., Battini, R., Sickl, E., de Leva, M. F., Boespflug‐Tanguy, O., … Santorelli, F. M. (2009). Screening of ARHSP‐TCC patients expands the spectrum of SPG11 mutations and includes a large scale gene deletion. Human Mutation, 30(3), E500–E519.
Elert‐Dobkowska, E., Stepniak, I., Krysa, W., Ziora‐Jakutowicz, K., Rakowicz, M., Sobanska, A., Pilch, J., Antczak‐Marach, D., Zaremba, J., & Sulek, A. (2019). Next‐generation sequencing study reveals the broader variant spectrum of hereditary spastic paraplegia and related phenotypes. Neurogenetics, 20(1), 27–38.
Fishilevich, S., Nudel, R., Rappaport, N., Hadar, R., Plaschkes, I., Stein, T. I., Rosen, N., Kohn, A., Twik, M., Safran, M., Lancet, D., & Cohen, D. (2017). GeneHancer: Genome‐wide integration of enhancers and target genes in GeneCards. Database, 2017, bax028. https://doi.org/10.1093/database/bax028
Günther, S., Elert‐Dobkowska, E., Soehn, A. S., Hinreiner, S., Yoon, G., Heller, R., Hellenbroich, Y., Hübner, C. A., Ray, P. N., Hehr, U., Bauer, P., Sulek, A., & Beetz, C. (2016). High frequency of pathogenic rearrangements in SPG11 and extensive contribution of mutational hotspots and founder alleles. Human Mutation, 37(7), 703–709.
Hourani, R., El‐Hajj, T., Barada, W. H., Hourani, M., & Yamout, B. I. (2009). MR imaging findings in autosomal recessive hereditary spastic paraplegia. American Journal of Neuroradiology, 30(5), 936–940.
Kara, E., Tucci, A., Manzoni, C., Lynch, D. S., Elpidorou, M., Bettencourt, C., Chelban, V., Manole, A., Hamed, S. A., Haridy, N. A., Federoff, M., Preza, E., Hughes, D., Pittman, A., Jaunmuktane, Z., Brandner, S., Xiromerisiou, G., Wiethoff, S., Schottlaender, L., … Houlden, H. (2016). Genetic and phenotypic characterization of complex hereditary spastic paraplegia. Brain, 139(7), 1904–1918.
Kragesteen, B. K., Brancati, F., Digilio, M. C., Mundlos, S., & Spielmann, M. (2019). H2AFY promoter deletion causes PITX1 endoactivation and Liebenberg syndrome. Journal of Medical Genetics, 56(4), 246–251.
Meyyazhagan, A., & Orlacchio, A. (2022). Hereditary spastic paraplegia: An update. International Journal of Molecular Sciences, 23(3), 1697.
Montecchiani, C., Pedace, L., Lo Giudice, T., Casella, A., Mearini, M., Gaudiello, F., Pedroso, J. L., Terracciano, C., Caltagirone, C., Massa, R., St George‐Hyslop, P. H., Barsottini, O. G. P., Kawarai, T., & Orlacchio, A. (2016). ALS5/SPG11/KIAA1840 mutations cause autosomal recessive axonal Charcot‐Marie‐Tooth disease. Brain, 139(Pt 1), 73–85.
Morais, S., Raymond, L., Mairey, M., Coutinho, P., Brandão, E., Ribeiro, P., Loureiro, J. L., Sequeiros, J., Brice, A., Alonso, I., & Stevanin, G. (2017). Massive sequencing of 70 genes reveals a myriad of missing genes or mechanisms to be uncovered in hereditary spastic paraplegias. European Journal of Human Genetics., 25(11), 1217–1228.
Nakamura, A., Izumi, K., Umehara, F., Kuriyama, M., Hokezu, Y., Nakagawa, M., Shimmyozu, K., Izumo, S., & Osame, M. (1995). Familial spastic paraplegia with mental impairment and thin corpus callosum. Journal of the Neurological Sciences, 131(1), 35–42.
Orlacchio, A., Babalini, C., Borreca, A., Patrono, C., Massa, R., Basaran, S., Munhoz, R. P., Rogaeva, E. A., St George‐Hyslop, P. H., Bernardi, G., & Kawarai, T. (2010). SPATACSIN mutations cause autosomal recessive juvenile amyotrophic lateral sclerosis. Brain, 133(Pt 2), 591–598.
Örlén, H., Melberg, A., Raininko, R., Kumlien, E., Entesarian, M., Söderberg, P., Påhlman, M., Darin, N., Kyllerman, M., Holmberg, E., Engler, H., Eriksson, U., & Dahl, N. (2009). SPG11 mutations cause Kjellin syndrome, a hereditary spastic paraplegia with thin corpus callosum and central retinal degeneration. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 150B(7), 984–992.
Pereira, M. C., Loureiro, J. L., Pinto‐Basto, J., Brandão, E., Lopes, A. M., Neves, G., Dias, P., Geraldes, R., Martins, I. P., Cruz, V. T., Kamsteeg, E. J., Brunner, H. G., Coutinho, P., Sequeiros, J., & Alonso, I. (2012). Alu elements mediate large SPG11 gene rearrangements: Further spatacsin mutations. Genetics in Medicine, 14(1), 143–151.
Pozner, T., Regensburger, M., Engelhorn, T., Winkler, J., & Winner, B. (2020). Janus‐faced spatacsin (SPG11): Involvement in neurodevelopment and multisystem neurodegeneration. Brain, 143(8), 2369–2379.
Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier‐Foster, J., Grody, W. W., Hegde, M., Lyon, E., Spector, E., & Voelkerding, K. (2015). Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genetics in Medicine, 17(5), 405–424.
Riggs, E. R., Andersen, E. F., Cherry, A. M., Kantarci, S., Kearney, H., Patel, A., Raca, G., Ritter, D. I., South, S. T., Thorland, E. C., Pineda‐Alvarez, D., Aradhya, S., & Martin, C. L. (2020). Technical standards for the interpretation and reporting of constitutional copy‐number variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen). Genetics in Medicine, 22(2), 245–257.
Sperfeld, A. D., Kassubek, J., Crosby, A. H., Winner, B., Ludolph, A. C., Uttner, I., & Hanemann, C. O. (2004). Complicated hereditary spastic paraplegia with thin corpus callosum: Variation of phenotypic expression over time. Journal of Neurology, 251(10), 1285–1287.
Stevanin, G., Azzedine, H., Denora, P., Boukhris, A., Tazir, M., Lossos, A., Rosa, A. L., Lerer, I., Hamri, A., Alegria, P., Loureiro, J., Tada, M., Hannequin, D., Anheim, M., Goizet, C., Gonzalez‐Martinez, V., le Ber, I., Forlani, S., Iwabuchi, K., … SPATAX consortium. (2008). Mutations in SPG11 are frequent in autosomal recessive spastic paraplegia with thin corpus callosum, cognitive decline and lower motor neuron degeneration. Brain, 131(3), 772–784.
Stevanin, G., Montagna, G., Azzedine, H., Valente, E. M., Durr, A., Scarano, V., Bouslam, N., Cassandrini, D., Denora, P. S., Criscuolo, C., Belarbi, S., Orlacchio, A., Jonveaux, P., Silvestri, G., Hernandez, A. M. O., de Michele, G., Tazir, M., Mariotti, C., Brockmann, K., … Santorelli, F. M. (2006). Spastic paraplegia with thin corpus callosum: Description of 20 new families, refinement of the SPG11 locus, candidate gene analysis and evidence of genetic heterogeneity. Neurogenetics, 7(3), 149–156.
Teive, H. A. G., Iwamoto, F. M., Coletta, M. V. D., Camargo, C. H., Bezerra, R. D., Minguetti, G., & Werneck, L. C. (2001). Hereditary spastic paraplegia associated with thin corpus callosum. ArqNeuropsiquiatr., 59(3B), 790–792.

Auteurs

Irene Mademont-Soler (I)

Àrea de Genètica Clínica i Consell Genètic, Laboratori Clínic Territorial Girona, Institut Català de la Salut, Girona, Spain.
Grup de Trastorns del Neurodesenvolupament, Institut Investigació Biomèdica de Girona, Girona, Spain.

Susanna Esteba-Castillo (S)

Grup de Trastorns del Neurodesenvolupament, Institut Investigació Biomèdica de Girona, Girona, Spain.
Servei Especialitzat en Salut Mental i Discapacitat Intel·Lectual, Institut d'Assistència Sanitària, Girona, Spain.

Aida Jiménez-Xifra (A)

Departament de Citogenètica, Reference Laboratory, Barcelona, Spain.

Berta Alemany (B)

Servei de Neurologia, Hospital Universitari de Girona Dr. Josep Trueta, Girona, Spain.

Núria Ribas-Vidal (N)

Grup de Trastorns del Neurodesenvolupament, Institut Investigació Biomèdica de Girona, Girona, Spain.
Servei Especialitzat en Salut Mental i Discapacitat Intel·Lectual, Institut d'Assistència Sanitària, Girona, Spain.

Maria Cutillas (M)

Àrea de Genètica Clínica i Consell Genètic, Laboratori Clínic Territorial Girona, Institut Català de la Salut, Girona, Spain.

Mònica Coll (M)

Unitat de Genòmica i Medicina Personalitzada, Laboratori Clínic Territorial Girona, Institut Català de la Salut, Girona, Spain.

Mel Lina Pinsach (ML)

Unitat de Genòmica i Medicina Personalitzada, Laboratori Clínic Territorial Girona, Institut Català de la Salut, Girona, Spain.

Sara Pagans (S)

Grup de Genètica Cardiovascular, Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta, Girona, Spain.

Mireia Alcalde (M)

Grup de Genètica Cardiovascular, Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta, Girona, Spain.

Marina Viñas-Jornet (M)

Departament de Genètica Molecular, qGenomics, Barcelona, Spain.

Mercedes Montero-Vale (M)

Departament de Genètica Molecular, qGenomics, Barcelona, Spain.

Marta de Castro-Miró (M)

Departament de Genètica Molecular, qGenomics, Barcelona, Spain.

Jairo Rodríguez (J)

Departament de Genètica Molecular, qGenomics, Barcelona, Spain.

Lluís Armengol (L)

Departament de Genètica Molecular, qGenomics, Barcelona, Spain.

Xavier Queralt (X)

Àrea de Genètica Clínica i Consell Genètic, Laboratori Clínic Territorial Girona, Institut Català de la Salut, Girona, Spain.

María Obón (M)

Àrea de Genètica Clínica i Consell Genètic, Laboratori Clínic Territorial Girona, Institut Català de la Salut, Girona, Spain.
Grup de Trastorns del Neurodesenvolupament, Institut Investigació Biomèdica de Girona, Girona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH